Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.

Timeline

Start

2019-03-29

Primary completion

2022-02-17

Completion

2022-02-17

Outcome

Met primary endpoint

paper tildrakizumab, an anti-interleukin-23 p19 antibody, met the primary efficacy endpoint at week 16. PMID 39722400 ↗

registry NUMBER Tildrakizumab: 0.494 proportion of subjects NCT03897088 ↗

registry Placebo Comparator: Placebo vs Tildrakizumab; p <0.00001; Cochran-Mantel-Haenszel NCT03897088 ↗

Publications

• Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks. Dermatol Ther (Heidelb). 2026 Jun;16(6):3151-3165. doi: 10.1007/s13555-026-01774-2. Epub 2026 May 9.
• Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2025 Apr;92(4):816-824. doi: 10.1016/j.jaad.2024.12.018. Epub 2024 Dec 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tildrakizumab	Monoclonal antibody	100 mg	—

Indications